Abstract

Understanding the molecular events controlling melanoma progression is of paramount importance for the development of alternative treatment options for this devastating disease. Here we report a mechanism regulated by the oncogenic SOX2-GLI1 transcriptional complex driving melanoma invasion through the induction of the sialyltransferase ST3GAL1. Using in vitro and in vivo studies, we demonstrate that ST3GAL1 drives melanoma metastasis. Silencing of this enzyme suppresses melanoma invasion and significantly reduces the ability of aggressive melanoma cells to enter the blood stream, colonize distal organs, seed and survive in the metastatic environment. Analysis of glycosylated proteins reveals that the receptor tyrosine kinase AXL is a major effector of ST3GAL1 pro-invasive function. ST3GAL1 induces AXL dimerization and activation that, in turn, promotes melanoma invasion. Our data support a key role of the ST3GAL1-AXL axis as driver of melanoma metastasis, and highlight the therapeutic potential of targeting this axis to treat metastatic melanoma.

Understanding the molecular events controlling melanoma progression are necessary to find improved therapeutics. Here, the authors report oncogenic SOX2-GLI1 transcriptional complex to drive melanoma invasion through the induction of the sialyltransferase ST3GAL1, and report ST3GAL1-AXL axis as driver of melanoma metastasis.

Details

Title
ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL
Author
Pietrobono Silvia 1   VIAFID ORCID Logo  ; Anichini Giulia 2 ; Sala Cesare 3   VIAFID ORCID Logo  ; Manetti Fabrizio 4 ; Almada, Luciana L 5 ; Pepe, Sara 6 ; Carr, Ryan M 5 ; Paradise, Brooke D 5 ; Sarkaria, Jann N 7   VIAFID ORCID Logo  ; Davila, Jaime I 8   VIAFID ORCID Logo  ; Tofani Lorenzo 9 ; Battisti Ilaria 10 ; Arrigoni Giorgio 11   VIAFID ORCID Logo  ; Li, Ying 12 ; Zhang, Cheng 13 ; Hu, Li 13   VIAFID ORCID Logo  ; Meves, Alexander 12   VIAFID ORCID Logo  ; Fernandez-Zapico, Martin E 5 ; Stecca, Barbara 14   VIAFID ORCID Logo 

 Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO), Florence, Italy 
 Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO), Florence, Italy; University of Siena, Department of Medical Biotechnologies, Siena, Italy (GRID:grid.9024.f) (ISNI:0000 0004 1757 4641) 
 University of Florence, Department of Clinical and Experimental Medicine, Florence, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304) 
 University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Siena, Italy (GRID:grid.9024.f) (ISNI:0000 0004 1757 4641) 
 Mayo Clinic, Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO), Florence, Italy (GRID:grid.66875.3a); University of Siena, Department of Medical Biotechnologies, Siena, Italy (GRID:grid.9024.f) (ISNI:0000 0004 1757 4641) 
 Mayo Clinic, Department of Radiation Oncology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic, Rochester, Department of Health Sciences Research, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 University of Florence, Department of Neurosciences, Psychology, Drug Research and Child Health, Florence, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304) 
10  University of Padova and Azienda Ospedaliera di Padova, Proteomics Center, Padova, Italy (GRID:grid.411474.3) (ISNI:0000 0004 1760 2630) 
11  University of Padova and Azienda Ospedaliera di Padova, Proteomics Center, Padova, Italy (GRID:grid.411474.3) (ISNI:0000 0004 1760 2630); University of Padova, Department of Biomedical Sciences, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470) 
12  Mayo Clinic, Department of Dermatology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
13  Mayo Clinic, Department of Molecular Pharmacology & Experimental Therapeutics, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
14  Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO), Florence, Italy (GRID:grid.66875.3a) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2471571250
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.